Vaccine approach extends life of metastatic prostate cancer patients

In a newly published clinical trial, patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine, researchers report.

Read the whole article on Science Daily

More from Science Daily